<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04285944</url>
  </required_header>
  <id_info>
    <org_study_id>S62469</org_study_id>
    <nct_id>NCT04285944</nct_id>
  </id_info>
  <brief_title>Operator Radiation Protection During Cardiac Catheterization Using Mavig X-ray Protective Drapes®.</brief_title>
  <official_title>Operator Radiation Protection During Cardiac Catheterization Using Mavig X-ray Protective Drapes®.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Interventional cardiologists are exposed to significant doses of scatter radiation during
      cardiac catheterization and percutaneous coronary intervention. Traditional methods of
      reducing the radiation dose for operators in the cardiac catheterization laboratory include
      limiting the use of radiation, radiation protection aprons and shields, and the use of lead
      eye glasses. Despite these measures several parts of the operators body, including the head
      and neck, are poorly screened from scatter radiation. Radiation protection drapes have been
      developed for use in cardiac catheterization but no randomized controlled study has yet been
      performed with the commercially available Mavig X-ray Protective Drapes®. The aim of this
      study is to evaluate operator radiation protection using Mavig X-ray Protective Drapes®.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Operator radiation dose</measure>
    <time_frame>Immediate</time_frame>
    <description>Gray</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Radiation Exposure</condition>
  <arm_group>
    <arm_group_label>Study</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mavig X-ray Protective Drapes</intervention_name>
    <description>Mavig X-ray Protective Drapes®</description>
    <arm_group_label>Study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient undergoing the procedure is older than 18 years and is planned for a coronary
             angiogram, cardiac catheterization and/or percutaneous coronary intervention.

          2. The coronary angiogram/cardiac catheterization/PCI procedure is elective.

          3. The patient undergoing the procedure is male, or if female, has no childbearing
             potential or is not pregnant.

        Exclusion Criteria:

        1. The procedure is an emergency and/or the patient is unstable. -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keir Mccutcheon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabine Van Roey</last_name>
    <phone>003216342465</phone>
    <phone_ext>+32468312267</phone_ext>
    <email>sabine.vanroey@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Keir Mccutcheon</last_name>
    <phone>+32468312267</phone>
    <phone_ext>+32468312267</phone_ext>
    <email>keir.mccutcheon@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Cardiovascular Disease, University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Van Roey</last_name>
      <phone>003216342465</phone>
      <email>sabine.vanroey@uzleuven.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Van Roey</last_name>
      <phone>+32 16 34 24 66</phone>
      <email>sabine.vanroey@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Keir McCutcheon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 24, 2020</study_first_submitted>
  <study_first_submitted_qc>February 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2020</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>Prof Dr Walter Desmet</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

